Tracers / [161Tb]Tb-TbCl3
[161Tb]Tb-TbCl3
Also written as [Tb-161]TbCl3
- Radionuclide
- Tb-161 t½ 9907.2 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 2
What it is
- Compound class
- —
- Target / mechanism
- —
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | custom manifold | — | 85-99% | ≥99.999% | 160Gd2O3 Isoflex, San Francisco, CA, USA | 42075874 2026 Pharmaceuticals (Basel) The separation process can be performed with manual fraction collecting even when processing high activity targets — The separation yields of purified 161Tb varied from 85 to 99%, with the activities of 9.9–22.1 GBq |
| Manual synthesis | custom manifold | — | 75-90% yes | — | [155Tb]TbCl3 | 34778932 2021 EJNMMI Radiopharm Chem a chemical separation system was designed, built, and introduced into a hot cell — The separation yield resulted in 75–90%, indicating that only 10–25% of terbium-155 activity were lost during separation |
Need this precursor?We can point you to suppliers for [161Tb]Tb-TbCl3, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 4 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.